Latest news
Scholar Rock (SRRK) Nears Approval for First Myostatin Inhibitor Amid High Price-to-Sales Valuation - GuruFocusGuruFocus · Thu, 06 Aug 2026 15:23:10 GMTScholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights - BioSpaceBioSpace · Thu, 06 Aug 2026 12:39:18 GMTBridging the Gap in SMA: Muscle-Targeted Treatments and the Promise of Myostatin Inhibitors - EMJEMJ · Fri, 31 Jul 2026 15:46:41 GMT